Overview
Tesamorelin is a 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH), modified with an N-terminal trans-3-hexenoic acid to resist degradation by dipeptidyl peptidase-4.
Mechanism
By binding the GHRH receptor on pituitary somatotrophs, tesamorelin promotes pulsatile growth-hormone release and a downstream rise in IGF-1. Clinical-trial literature reports preferential reduction in visceral adipose tissue at the dosing regimens studied.
Notes for the lab
Lyophilized tesamorelin is reconstituted with sterile diluent and kept cold. Most published human PK data use subcutaneous administration; storage conditions and reconstitution volume affect potency and should be controlled per protocol.